The FLOW phase 3 trial also demonstrated a 24 percent reduction in the risk of composite renal disease endpoints
Beyond-use date (BUD): Assigned to compounded medications by the pharmacist
Cardiovascular Risk Reduction : For adults with type 2 diabetes and established heart and blood vessel disease, Semaglutide can significantly reduce the risk of major cardiovascular events like heart attack, stroke, or death
Benefits and risks of high vitamin E intake or supplements High vitamin E intake from food or supplements has been linked with a number of benefits
Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample
To view or add a comment, sign in HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF): SEMAGLUTIDE AND TIRZEPATIDE SHOWED MORE THAN 40% RISK REDUCTION In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy
